Companies
MaaT Pharma
A Lyon-based pioneer in high-diversity microbial ecosystems for oncology; lead drug MaaT013 reached pivotal phase 3 in Europe for acute graft-versus-host disease with an automated GMP plant.
- Country
- France
- Ticker
- EPA:ALMAAT
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | €37.5 million loan from European Investment Bank (EIB) secured in July 2025 | maatpharma.com |
| Capacity | 9,000 pouches of MaaT013 and 1.3 million capsules of MaaT033 per year | pharmaceutical-technology.com |
| Regulatory approval | Marketing Authorization Application for Xervyteg (MaaT013) submitted in June 2025; received negative CHMP opinion in May/June 2026; re-examination planned | maatpharma.com |
| Production site | cGMP facility in Saint-Quentin-Fallavier, near Lyon, France | pharmaceutical-technology.com |
| Revenue | €4.5 million in 2025; €0.8 million in Q1 2026 | live.euronext.com · maatpharma.com |
Independent sources: live.euronext.com · pharmaceutical-technology.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Microbiome therapeutics (live biotherapeutic products) | therapeutics-platforms | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.